The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Improved survival in women with BRCA‐associated ovarian carcinoma
Open accessAbstract
BACKGROUND: The objective of this study was to determine the clinical characteristics, treatment response, and frequency of p53 overexpression in Ashkenazi Jewish women with hereditary ovarian carcinoma. METHODS: Seventy‐one Jewish women with epithelial ovarian carcinoma (EOC) were tested for the three BRCA founder mutations using single‐strand conformation polymorphism analysis, heteroduplex analysis, and protein truncation testing. Clinical and histopathologic data were reviewed retrospectively. In vitro chemoresistance was analyzed in 32 patients. Mutations of p53 were studied using immunohistochemical detection of p53 overexpression. RESULTS: Thirty‐four of 71 Jewish patients with EOC (48%) had germline BRCA mutations (BRCA heterozygotes), including 22 BRCA1 mutations and 12 BRCA2 mutations. BRCA heterozygotes were younger compared with Jewish patients who had EOC without mutations (sporadic carcinoma; 50 years vs. 59 years, respectively; P = 0.01). BRCA1 heterozygotes were younger compared with BRCA2 heterozygotes (48 years vs. 57 years, respectively; P = 0.01). Histopathologic tumor features were similar; however, tumors with low malignant potential were seen only in women with sporadic carcinoma. Both groups had equivalent rates of surgical cytoreduction and similar median follow‐up (72 months). BRCA heterozygotes had higher response rates to primary therapy compared with patients who had sporadic disease (P = 0.01). In vitro chemoresistance predicted tumor response to platinum chemotherapy correctly in BRCA heterozygotes (P = 0.0096). BRCA heterozygotes with advance‐stage disease had improved survival compared with patients who had advanced stage sporadic carcinoma (91 months vs. 54 months, respectively; P = 0.046) and had a longer disease free interval (49 months vs. 19 months, respectively; P = 0.16). p53 overexpression was common in BRCA heterozygotes (80%). CONCLUSIONS: BRCA1 heterozygotes developed EOC at a younger age compared with BRCA2 heterozygotes and women who had sporadic ovarian carcinoma. BRCA heterozygotes had a better response to platinum chemotherapy compared with women who had sporadic disease, which may have contributed to their improved prognosis. Cancer 2003;97:2187–95. © 2003 American Cancer Society. DOI 10.1002/cncr.11310
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Self-citationBristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Gene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,733
Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells
Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81847-4 · Cited by 1,459
Cortez, D., Wang, Y., Qin, J., & Elledge, S. J. (1999) · Science · doi:10.1126/science.286.5442.1162 · Cited by 1,020
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Self-citationPrevalence of BRCA1 and BRCA2 Gene Mutations in Patients With Early-Onset Breast Cancer
Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D. F., Evans, C., Deacon, J., & Stratton, M. R. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.943 · Cited by 873
Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X.-W., Harris, C. C., Ried, T., & Deng, C.-X. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80466-9 · Cited by 819
Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Brose, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1365 · Cited by 728
BRCA2 Function in DNA Binding and Recombination from a BRCA2-DSS1-ssDNA Structure
Yang, H., Jeffrey, P. D., Miller, J., Kinnucan, E., Sun, Y., Thomä, N. H., Zheng, N., Chen, P.-L., Lee, W.-H., & Pavletich, N. P. (2002) · Science · doi:10.1126/science.297.5588.1837 · Cited by 705
The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the Mouse
Hakem, R., de la Pompa, J. L., Sirard, C., Mo, R., Woo, M., Hakem, A., Wakeham, A., Potter, J., Reitmair, A., Billia, F., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81302-1 · Cited by 667
Struewing, J. P., Abeliovich, D., Peretz, T., Avishai, N., Kaback, M. M., Collins, F. S., & Brody, L. C. (1995) · Nature Genetics · doi:10.1038/ng1095-198 · Cited by 647
Thompson, M. E., Jensen, R. A., Obermiller, P. S., Page, D. L., & Holt, J. T. (1995) · Nature Genetics · doi:10.1038/ng0495-444 · Cited by 585
Ludwig, T., Chapman, D. L., Papaioannou, V. E., & Efstratiadis, A. (1997) · Genes & Development · doi:10.1101/gad.11.10.1226 · Cited by 539
Clinicopathologic Features of <EMPH TYPE="ITAL">BRCA</EMPH>-Linked and Sporadic Ovarian Cancer
Boyd, J. (2000) · JAMA · doi:10.1001/jama.283.17.2260 · Cited by 536
BRCA1 physically associates with p53 and stimulates its transcriptional activity
Zhang, H., Somasundaram, K., Peng, Y., Tian, H., Zhang, H., Bi, D., Weber, B. L., & El-Deiry, W. S. (1998) · Oncogene · doi:10.1038/sj.onc.1201932 · Cited by 492
Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1
Rubin, S. C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M. A., LiVolsi, V. A., Berchuck, A., Muto, M. G., Garber, J. E., Weber, B. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611073351901 · Cited by 423
Oddoux, C., Struewing, J. P., Clayton, C. M., Neuhausen, S., Brody, L. C., Kaback, M., Haas, B., Norton, L., Borgen, P., Jhanwar, S., et al. (1996) · Nature Genetics · doi:10.1038/ng1096-188 · Cited by 381
Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G., Sagi, M., Zlotogora, J., Heching, N. I., & Peretz, T. (1997) · Europe PMC (PubMed Central) · Cited by 357
Tirkkonen, M., Johannsson, O. T., Agnarsson, B. A., Olsson, H. L., Ingvarsson, S., Karhu, R., Tanner, M., Isola, J. J., Barkardottir, R. B., Borg, Å., et al. (1997) · PubMed · Cited by 354
Levy‐Lahad, E., Catane, R., Eisenberg, S., Kaufman, B., Hornreich, G., Lishinsky, E., Shohat, M., Weber, B., Beller, U., Lahad, A., et al. (1997) · Europe PMC (PubMed Central) · Cited by 316
BRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian Cancer
Moslehi, R., Chu, W., Karlan, B., Fishman, D., Risch, H., Fields, A., Smotkin, D., Ben-David, Y., Rosenblatt, J., Russo, D., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/302853 · Cited by 314
Self-citationHusain, A., He, G., Venkatraman, E. S., & Spriggs, D. R. (1998) · PubMed · Cited by 291
Righetti, S. C., Torre, G. D., Pilotti, S., Ménard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C. E., Cornarotti, M., Oriana, S., et al. (1996) · PubMed · Cited by 276
Narod, S. A., Ford, D., Devilee, P., Barkardottir, R. B., Lynch, H. T., Smith, S. A., Ponder, B. A. J., Weber, B. L., Garber, J. E., & Birch, J. M. (1995) · Europe PMC (PubMed Central) · Cited by 265
Self-citationSurvival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Jóhannsson, O. T., Ranstam, J., Borg, A., & Olsson, H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.397 · Cited by 254
Partial rescue of Brca15–6 early embryonic lethality by p53 or p21 null mutation
Hakem, R., de la Pompa, J. L., Elia, A., Potter, J., & Mak, T. W. (1997) · Nature Genetics · doi:10.1038/ng0797-298 · Cited by 252
BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair
Hartman, A.-R., & Ford, J. M. (2002) · Nature Genetics · doi:10.1038/ng953 · Cited by 233
A Genetic Epidemiological Study of Carcinoma of the Fallopian Tube
Aziz, S., Kuperstein, G., Rosen, B., Cole, D., Nedelcu, R., McLaughlin, J., & Narod, S. A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6095 · Cited by 222
Self-citationAnticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.
Struewing, J. P., Lerman, C., Kase, R. G., Giambarresi, T. R., & Tucker, M. A. (1995) · PubMed · Cited by 214
Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors
David, Y. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.463 · Cited by 200
Crook, T., Brooks, L. A., Crossland, S., Osin, P., Barker, K. T., Waller, J., Philp, E., Smith, P. D., Yulug, I., Peto, J., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1202106 · Cited by 179
p53 mutations in BRCA1-associated familial breast cancer
Crook, T., Crossland, S., Crompton, M. R., Osin, P., & Gusterson, B. A. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63327-2 · Cited by 179
Kern, D. H., & Weisenthal, L. M. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.7.582 · Cited by 174
Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors
Hartmann, J. T., Fossa, S. D., Nichols, C. R., Droz, J.-P., Horwich, A., Gerl, A., Beyer, J., Pont, J., Fizazi, K., Hecker, H., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1733 · Cited by 162
Grann, V. R., Jacobson, J. S., Thomason, D., Hershman, D. L., Heitjan, D. F., & Neugut, A. I. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.101 · Cited by 154
Buttitta, F., Marchetti, A., Gadducci, A., Pellegrini, S., Morganti, M., Carnicelli, V., Cosio, S., Gagetti, O., Genazzani, A. R., & Bevilacqua, G. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.38 · Cited by 153
Prognostic significance of p53 immunostaining in epithelial ovarian cancer.
Hartmann, L. C., Podratz, K. C., Keeney, G. L., Kamel, N. A. M. H., Edmonson, J. H., Grill, J., su, J., Katzmann, J. A., & Roche, P. C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.64 · Cited by 148
p53 Mutations and Expression in Ovarian Cancers: Correlation with Overall Survival
Wen, W., Reles, A., Runnebaum, I. B., Sullivan‐Halley, J., Bernstein, L., Jones, L. A., Felix, J. C., Kreienberg, R., El‐Naggar, A. K., & Press, M. F. (1999) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199901000-00005 · Cited by 143
Pharoah, P., Easton, D. F., Stockton, D., Gayther, S. A., & Ponder, B. A. J. (1999) · PubMed · Cited by 139
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Phillips, K., Nichol, K., Ozçelik, H., Knight, J., Done, S., Goodwin, P., & Andrulis, I. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.469 · Cited by 111
Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.
Aida, H., Takakuwa, K., Nagata, H., et al. (1998) · PubMed · Cited by 99
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Rhei, E., Bogomolniy, F., Federici, M. G., Maresco-Pennisi, D. L., Offit, K., Robson, M. E., Saigo, P. E., & Boyd, J. (1998) · PubMed · Cited by 98
An overview of the status of imaging screening technology for breast cancer
Smith, J. A., & Andreopoulou, E. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh653 · Cited by 91
Rates of Jewish Ancestral Mutations in BRCAI and BRCA2 in Borderline Ovarian Tumors
Gotlieb, W. H., Ben‐Baruch, G., Friedman, E., Bar-Sade, R. B., Сергеевна, К. А., Hirsh‐Yechezkel, G., Modan, B., Novikov, I., Davidson, B., Kopolovic, J., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.13.995 · Cited by 50
Leitão, M. M., & Boyd, J. A. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2001.6538 · Cited by 3
Cited by
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationDNA interstrand crosslink repair and cancer
Deans, A. J., & West, S. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3088 · Cited by 1,023
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Metadata
- Authors
- Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-04-17
- Volume
- 97
- Issue
- 9
- Pages
- 2187-2195
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2059000312
- Cited by
- 433
- References
- 49
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.